NCT06524544 2026-03-18A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial CancerNational Cancer Institute (NCI)Phase 3 Recruiting320 enrolled